Analyst Price Target is $27.00
▼ -53.97% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $27.00, with a high forecast of $34.00 and a low forecast of $20.00. The average price target represents a -53.97% upside from the last price of $58.66.
Current Consensus is
The current consensus among 5 investment analysts is to hold stock in Cortexyme. This rating has held steady since November 2020, when it changed from a Buy consensus rating.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.